Advancements in Personalized Cellular Immunotherapy

Arun Kumar Singh has completed his Master of Pharmacy (M. Pharm) in Pharmaceutics from Galgotias University, Greater Noida, India. Currently, he is serving as an Assistant Professor in the Department of Pharmacy at Vivekanand Global University, where he is actively engaged in both teaching and research.His research interests encompass a wide range of emerging and interdisciplinary fields, including nano-formulation, blockchain technology, the Internet of Things (IoT), machine learning, cancer biology, artificial intelligence, big data analytics, and neuroscience. Demonstrating a strong commitment to academic excellence, Mr. Singh has made significant contributions to the scientific community.He has authored one book with IOP Publishing and has contributed five book chapters in the field of big data with the prestigious River Publishers, Denmark. Furthermore, he has published 28 review articles in reputed journals, including two high-impact papers in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. His research work reflects a cumulative impact factor of 95.6, underlining the quality and influence of his scholarly contributions.In addition to journal publications, Mr. Singh has authored and edited 58 books with internationally recognized publishers such as IOP Publishing, Elsevier, CRC Press, and Wiley, demonstrating his broad expertise and dedication to advancing knowledge in pharmaceutical sciences and related areas.Mr. Singh is known for his exceptional research skills, innovative thinking, leadership qualities, effective decision-making, and positive outlook. His diligent work ethic and unwavering commitment to academic and research excellence set him apart as an extraordinary professional in his field.With a passion for driving innovation and fostering interdisciplinary collaboration, Arun Kumar Singh continues to contribute to the growth of pharmaceutical sciences and aims to make a lasting impact in healthcare and technology-driven research.Dr. Murali Yallapu is a tenured Associate Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology, and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal-1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including the Cleveland Clinic and the University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews. His primary research focuses on developing nanomaterials for enhanced therapeutic potential and cancer immunotherapy.Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, including Elsevier, Springer, and British Medical JournalDr. Pranav Kumar Prabhakar is currently working as a Professor and Head at Department of Biotechnology, School of Engineering and Technology, Nagaland University, Meriema, Kohima, Nagaland, India. He is among the World’s Top 2% Scientists (list published by Stanford University, USA, 2021, 2022, 2023, 2024, and 2025). He completed his PhD in Biotechnology from IIT Madras. His research focuses on elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. Dr. Pranav is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He serves as an editorial board member and reviewer for many reputed national and international journals. His honors include a travel grant from IIT Madras and the Council for Scientific and Industrial Research (CSIR) to attend ATTD 2009 in Greece, approved by the Department of Science and Technology (DST). He has published over 160+ research articles, authored/edited 24 books, and 48 book chapters, and delivered 9 oral and poster presentations at scientific meetings.

• 1. Introduction to Personalized Cellular Immunotherapy2. Understanding the therapeutic significance of tumor-infiltrating immune cells and their characteristics: a historical overview of cancer immunotherapy3. A groundbreaking development in cancer treatment: chimeric antigen receptor CART-cell therapy4. Recent Progress in CAR-T Cell Therapy for B Cell Cancers with Resistant Tissues5. Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: new perspectives6. The use of oncolytic viruses delivered by mesenchymal stromal cells in immunotherapy for the treatment of metastatic tumors7. Cancer Treatment Advancements in the Era of Immune Checkpoint Inhibitors via Cellular Immunotherapies8. The future of cancer immunotherapy: combining gene and cellular approaches9. Platelet Shielding of Cancer Cells: Implications for Immunotherapy Strategies10. Cancer Cell-Platelet Interactions: Harnessing Therapeutic Opportunities in Cancer Treatment11. Myeloid-Derived Suppressor Cells: A Promising Target for Anticancer Immunotherapy12. Utilizing Nanomedicines to Modulate Myeloid-Derived Suppressor Cells: Enhancing Cancer Immunotherapy13. Unlocking the Potential of Macrophages: Advancements in Cellular Immunotherapy14. Combination therapy: a new strategy to manage cancer15. Future perspective of cellular immunotherapy in cancer treatment